The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. - Wikidata - awgldk - TriplyDB

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

http://www.wikidata.org/entity/Q44697461

about

5-alpha-reductase inhibitors for prostate cancer prevention Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia Serenoa repens for benign prostatic hyperplasia Finasteride for benign prostatic hyperplasia Serenoa repens for benign prostatic hyperplasia 5alpha-reductase: history and clinical importance Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men New therapeutic strategies for the treatment of male lower urinary tract symptoms Recent advances in treatment for Benign Prostatic Hyperplasia Korean clinical practice guideline for benign prostatic hyperplasia Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review The many ways to make a luminal cell and a prostate cancer cell Update on medical therapy for male LUTS Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial Ejaculatory dysfunction in the treatment of lower urinary tract symptoms The pathophysiology of delayed ejaculation Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia Genetic association between PSA-158G/A polymorphism and the susceptibility of benign prostatic hyperplasia: a meta-analysis.Drug interactions between antiretrovirals and drugs used to treat benign prostatic hyperplasia/lower urinary tract symptoms.The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia.Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia.Moxibustion as an adjuvant for benign prostatic hyperplasia with lower urinary tract symptoms: a protocol for a parallel-group, randomised, controlled pilot trial.Testosterone and 17β-estradiol induce glandular prostatic growth, bladder outlet obstruction, and voiding dysfunction in male mice Prevalence of low testosterone in aging men with benign prostatic hyperplasia: data from the Proscar Long-term Efficacy and Safety Study (PLESS).Free prostate-specific antigen provides more precise data on benign prostate volume than total prostate-specific antigen in korean population Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism.Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials.Nanostructured systems containing babassu (Orbignya speciosa) oil as a potential alternative therapy for benign prostatic hyperplasia [Combined treatment of BPS with tamsulosin and finasteride : Literature review and prescription data].Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy.Silodosin for benign prostatic hyperplasia.Dropout in a longitudinal, cohort study of urologic disease in community men.Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment.A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium.

P2860

Q22252970-4D6A51CE-0531-45DF-8BEB-7D06A0FE994E Q24199135-2F884684-692F-4ED6-89F4-C57EEB308116 Q24202555-93EFFCCD-AC7F-40A8-AC74-CDF7D0E4234A Q24234464-D8187BA7-9E97-46C8-9445-BD75B36FCD65 Q24241144-E4DE75E8-481C-456B-A936-F09433E1EC42 Q24546176-80422AA0-3786-47A5-911E-5F1B828576F1 Q24649617-B15B7EDA-A33A-49DF-89D2-E4D8184F78D8 Q24658075-FD24205A-4FB0-40F2-B96E-31B39EE225B1 Q26746138-65D0FF0A-2BAF-474C-9CBF-E477802D2081 Q26766218-41A3587C-B9CB-45D9-892D-CC0807D0052E Q26766302-F76EE797-24C0-480C-B49B-6BD8F377B758 Q26770425-3AB1DB8F-0D99-448C-9B4C-FC16FC8D84DC Q26782663-3EADC91C-6299-43BC-87EC-6D4AE28FEC2E Q26785752-492603F8-FD25-41D1-B020-233E35281911 Q26797386-C1E525CA-76A2-4DA0-B43A-AA0716A10627 Q26862710-11D481B2-4A71-4361-BDBA-B81CBFE58B79 Q27008847-CE9C96BB-AE3D-4F9F-9CC1-BD2A4DAF2562 Q27009177-1E723921-604F-4C4E-8435-7FF52B01DF02 Q28073775-221DEFC8-736E-4FD0-9F8D-D5FDFAD6180F Q28074466-019C394C-2149-4B8C-A7D2-320E3D41AAC9 Q28077954-AD277756-D09A-45A5-B975-7B6EAC55375D Q30234717-2F38DEBE-3815-4B93-9C4E-92FFD13152FB Q30249162-C6716DA4-E44A-4B0F-AA39-536A29E2ECA7 Q30413910-D70E73D2-4147-4E69-958B-D6D7349FDFA0 Q30424857-7CEB2ACC-21E7-4D23-9D39-1BF8B34BED0C Q30427093-BFE409A1-9565-4C53-87D8-8BC1606E655D Q30432603-23571D0D-F20C-4D0B-A31F-24157B8902A1 Q30488666-E0377A3B-F957-4663-8F47-647181149456 Q30525673-D177A7FB-B4B8-4A51-915E-78A5F0D2E27C Q30597556-A1216DE1-5212-49A1-BC41-2FF6A9599310 Q30656133-DA6CC0B0-4B7B-4A30-B666-5AA8A8C4DC76 Q30962192-E40AD4B9-F809-4732-8720-D7CF63559BB5 Q31112168-243E5FC7-8C88-4F4B-A5D0-5D59476D1BC8 Q31128985-2CDFAE95-2026-476B-88BF-E47287D0BE35 Q31149371-F0DB16DD-8188-46CE-8493-21BF430FF288 Q33156578-C683A335-21E6-40D7-A52E-CD8E049B7B6B Q33158241-300EEF27-5EBF-44C5-AB40-52381F841D1E Q33266615-74917FDC-AB6E-4377-8654-9C3F75C2B414 Q33289952-F5D2574F-1CBA-485E-A70F-48C6B21DD41D Q33320106-22D0197B-D390-49B4-9D6E-ED2B9B2E2194

P2860

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

http://www.wikidata.org/entity/Q44697461

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

The long-term effect of doxazo ...... benign prostatic hyperplasia.

@en

The long-term effect of doxazo ...... benign prostatic hyperplasia.

@nl

type

label

The long-term effect of doxazo ...... benign prostatic hyperplasia.

@en

The long-term effect of doxazo ...... benign prostatic hyperplasia.

@nl

prefLabel

The long-term effect of doxazo ...... benign prostatic hyperplasia.

@en

The long-term effect of doxazo ...... benign prostatic hyperplasia.

@nl

P1433

Q44697461-8F940223-31C4-4E39-83E1-DD4B57E82289

P1476

Q44697461-96836C7E-8E3A-44A2-821A-AC32822781FB

P2093

Q44697461-0939D2E4-0B9D-41EE-8960-C82B52929CF6

Q44697461-0D0A2911-FEB1-4CA4-8809-8D0328B8AD7C

Q44697461-13B5DEF9-3846-48D3-A23E-F5AFBAD77313

Q44697461-1769641F-542B-4915-80C1-571C6F81AEE8

Q44697461-1B730639-64EF-4CE3-AD39-DD5173FA558E

Q44697461-3350AB4F-F73E-4C77-8B51-B858A2A27472

Q44697461-3BA37C0C-7F8A-4275-B5AA-77B9C2BB1DEA

Q44697461-3CAC6DCC-165B-4359-885C-2025CCE8F4A8

Q44697461-5807F90F-BCF2-4678-8F6F-F8B4204C544E

Q44697461-5A65BE84-3440-4D75-8090-76F764C20C5A

P304

Q44697461-ED5E7280-3DA9-4315-AFFD-14D8501CF7B1

P31

Q44697461-3BC7D1F5-C5E6-4A95-BB5B-2EDE57523C8E

P356

Q44697461-F81521DE-6161-47AC-92FE-1039B386035C

P407

Q44697461-033249E0-1071-416D-AE40-B0EB6F066382

P433

Q44697461-3E66C64F-2B0C-44F4-859B-AFDFA40C6977

P478

Q44697461-B156A0D3-724D-4D40-8281-4FAE711D1966

P577

Q44697461-14E37FF0-6824-43E7-A5B8-1882EED9D8F6

P698

Q44697461-1CDA4F22-D7E1-414E-8874-4DB14181C38E

P356

P1433

The New England Journal of Medicine

P1476

The long-term effect of doxazo ...... benign prostatic hyperplasia.

@en

P2093

Ananias Diokno

http://www.w3.org/2001/XMLSchema#string

Christopher M Dixon

http://www.w3.org/2001/XMLSchema#string

Claus G Roehrborn

http://www.w3.org/2001/XMLSchema#string

Douglas F Milam

http://www.w3.org/2001/XMLSchema#string

E David Crawford

http://www.w3.org/2001/XMLSchema#string

Gary J Miller

http://www.w3.org/2001/XMLSchema#string

Gerald L Andriole

http://www.w3.org/2001/XMLSchema#string

Harris E Foster

http://www.w3.org/2001/XMLSchema#string

Harry S Clarke

http://www.w3.org/2001/XMLSchema#string

Herbert Lepor

http://www.w3.org/2001/XMLSchema#string

P304

2387-2398

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA030656

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

349

http://www.w3.org/2001/XMLSchema#string

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14681504

http://www.w3.org/2001/XMLSchema#string